Zoetis Inc. (ZTS) · Aug 6, 2026 · Company update

Guidance slashed as U.S. pet weakness overwhelms a near-consensus quarter

Guidance slashed as U.S. pet weakness overwhelms a near-consensus quarter

The quarter itself was roughly in line, not a clean beat. Adjusted diluted EPS was $1.87 versus published expectations around $1.85–$1.88, while revenue of $2.468 billion was slightly below consensus near $2.49 billion.

MetricQ2 2026Q2 2025ChangeExternal expectation
Revenue$2.468B$2.474BFlat; (1)% organic operational~$2.49B–$2.52B
Adjusted diluted EPS$1.87$1.785% reported; 4% organic operational~$1.85–$1.88
GAAP diluted EPS$1.65$1.631%—
Adjusted net income$781M$791M(1)% reported; (2)% organic operational—
Full-year revenue guidance$9.12B–$9.32BPrior: $9.68B–$9.96BCut by $560M at the midpoint—
Full-year adjusted diluted EPS guidance$6.15–$6.25Prior: $6.85–$7.00Cut by $0.73 at the midpoint—

The decisive news is the full-year reset, not the quarterly EPS. Zoetis cut its 2026 revenue outlook by roughly 6% at the midpoint and adjusted EPS guidance by roughly 11%, while shifting expected organic operational performance from 2%–5% growth to a 3%–1% decline. The filing also raises expected significant items and acquisition-related costs from approximately $100 million to $150 million. (Full-Year 2026 Guidance)

U.S. companion-animal weakness is broader and more persistent than the prior outlook assumed. U.S. revenue fell 7% organically, with companion-animal sales down 11%; management cited lower clinic visits, pet-owner price sensitivity, competition in dermatology and Simparica Trio, generic pressure on Cerenia and Convenia, and lower Librela sales. U.S. earnings declined 10%, and gross margin fell to 83.1% from 84.7%. (Revenue by Segment and Species; Segment Earnings)

International and livestock provide real offsets, but not enough to repair the core problem. International revenue grew 6% organically and livestock revenue grew 11% organically, led by cattle and poultry. Those gains were outweighed by a 6% organic decline in companion-animal revenue globally and the 7% organic decline in the U.S. business. (Revenue by Segment and Species)

Net read: materially worse than the market’s standing expectation despite a near-consensus quarter. The current period shows cost control and strong livestock/international execution, but the sharply reduced full-year targets indicate management now expects the U.S. companion-animal slowdown to persist. That guidance cut substantially outweighs the small quarterly EPS-versus-consensus advantage. (Full-Year 2026 Guidance; Segment Earnings)

Original filing on SEC EDGAR

More Zoetis Inc. news

Guidance slashed as U.S. pet weakness overwhelms a near-consensus quarter | ZTS Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.